Posted by Michael Wonder on 10 Dec 2020
Lantheus Holdings announces acceptance and priority review of new drug application for PyLTM (18F DCFPyL), a PSMA targeted prostate cancer PET imaging agent
9 December 2020 - PDUFA action date of 28 May 2021 assigned by U.S. FDA.
Lantheus Holdings and Progenics Pharmaceuticals today announced that the U.S. FDA has accepted the new drug application for PyLTM (18F DCFPyL), a prostate specific membrane antigen (PSMA) targeted positron emission tomography imaging agent for prostate cancer.
